S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.48 (+1.66%)
AAPL   143.11 (+4.01%)
MSFT   260.65 (+3.20%)
FB   196.23 (+1.39%)
GOOGL   2,229.76 (+2.37%)
AMZN   2,151.14 (-0.03%)
TSLA   674.90 (+1.66%)
NVDA   168.98 (+1.22%)
BABA   87.23 (+0.51%)
NIO   16.00 (-2.68%)
AMD   95.07 (+1.68%)
CGC   5.19 (-5.98%)
MU   69.59 (+1.00%)
T   20.74 (+1.67%)
GE   75.46 (+0.28%)
F   12.83 (+2.64%)
DIS   105.83 (+3.33%)
AMC   11.58 (-3.74%)
PFE   52.88 (+0.78%)
PYPL   81.18 (+0.79%)
NFLX   187.44 (+0.58%)
NASDAQ:ENTX

Entera Bio (ENTX) Stock Forecast, Price & News

$2.40
-0.10 (-4.00%)
(As of 05/23/2022 04:00 PM ET)
Add
Compare
Today's Range
$2.29
$2.44
50-Day Range
$2.00
$2.95
52-Week Range
$1.72
$8.68
Volume
16,778 shs
Average Volume
77,960 shs
Market Capitalization
$56.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.64
30 days | 90 days | 365 days | Advanced Chart
Receive ENTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

Entera Bio logo

About Entera Bio

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
18
Year Founded
N/A

Sales & Book Value

Annual Sales
$570 thousand
Book Value
$0.83 per share

Profitability

Net Income
$-12.19 million
Net Margins
-1,345.02%
Pretax Margin
-2,847.93%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$56.88 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/23/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.58 out of 5 stars

Medical Sector

994th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

155th out of 211 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Entera Bio (NASDAQ:ENTX) Frequently Asked Questions

Is Entera Bio a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Entera Bio stock.
View analyst ratings for Entera Bio
or view top-rated stocks.

When is Entera Bio's next earnings date?

Entera Bio is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our earnings forecast for Entera Bio
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) issued its earnings results on Thursday, May, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. Entera Bio had a negative trailing twelve-month return on equity of 27.70% and a negative net margin of 1,345.02%. During the same quarter in the prior year, the business earned ($0.43) earnings per share.
View Entera Bio's earnings history
.

What price target have analysts set for ENTX?

2 equities research analysts have issued 12-month target prices for Entera Bio's stock. Their forecasts range from $6.00 to $12.00. On average, they expect Entera Bio's share price to reach $9.00 in the next year. This suggests a possible upside of 283.0% from the stock's current price.
View analysts' price targets for Entera Bio
or view top-rated stocks among Wall Street analysts.

Who are Entera Bio's key executives?
Entera Bio's management team includes the following people:
  • Dr. Hillel Galitzer, Chief Operating Officer (Age 44, Pay $359k)
  • Dr. Phillip Schwartz Ph.D., Exec. VP, Pres of R&D and Director (Age 60, Pay $441k)
  • Dr. Arthur C. Santora II, M.D., Ph.D., Chief Medical Officer (Age 71, Pay $355k)
  • Dr. Spiros Jamas Sc.D., Chief Exec. Officer (Age 61)
  • Ms. Dana Yaacov-Garbeli CPA, Chief Financial Officer (Age 39)
  • Dr. Roger J. Garceau FAAP, M.D., Chief Devel. Advisor & Director (Age 68)
  • Mr. Ramesh Ratan, U.S. Chief Financial Officer
What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include (CGC), Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an IPO on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group acted as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Who are Entera Bio's major shareholders?

Entera Bio's stock is owned by many different retail and institutional investors. Top institutional investors include PNC Financial Services Group Inc. (0.04%). Company insiders that own Entera Bio stock include Ramesh Ratan, Ron Mayron and Yonatan Malca.
View institutional ownership trends for Entera Bio
.

Which major investors are buying Entera Bio stock?

ENTX stock was acquired by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc.. Company insiders that have bought Entera Bio stock in the last two years include Ramesh Ratan, Ron Mayron, and Yonatan Malca.
View insider buying and selling activity for Entera Bio
or or view top insider-buying stocks.

How do I buy shares of Entera Bio?

Shares of ENTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $2.35.

How much money does Entera Bio make?

Entera Bio has a market capitalization of $55.70 million and generates $570 thousand in revenue each year. The company earns $-12.19 million in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does Entera Bio have?

Entera Bio employs 18 workers across the globe.

What is Entera Bio's official website?

The official website for Entera Bio is www.enterabio.com.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The company can be reached via phone at (722) 532-7151 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.